NeuroPace, Inc. (NPCE)

CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical Contrast

Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE

Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc.

NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace Q2 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now